A citation-based method for searching scientific literature

Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger, John K Chan, Susan A Davidson, Robert S Mannel, Paul A DiSilvestro, Heather A Lankes, Nilsa C Ramirez, Mary Claire King, Elizabeth M Swisher, Michael J Birrer. JAMA Oncol 2016
Times Cited: 326







List of co-cited articles
913 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
5

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
947
5

Patterns and functional implications of rare germline variants across 12 cancer types.
Charles Lu, Mingchao Xie, Michael C Wendl, Jiayin Wang, Michael D McLellan, Mark D M Leiserson, Kuan-Lin Huang, Matthew A Wyczalkowski, Reyka Jayasinghe, Tapahsama Banerjee,[...]. Nat Commun 2015
130
5

Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.
Lisa R Susswein, Megan L Marshall, Rachel Nusbaum, Kristen J Vogel Postula, Scott M Weissman, Lauren Yackowski, Erica M Vaccari, Jeffrey Bissonnette, Jessica K Booker, M Laura Cremona,[...]. Genet Med 2016
144
5

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Rachel Pearlman, Wendy L Frankel, Benjamin Swanson, Weiqiang Zhao, Ahmet Yilmaz, Kristin Miller, Jason Bacher, Christopher Bigley, Lori Nelsen, Paul J Goodfellow,[...]. JAMA Oncol 2017
235
5

A PALB2 mutation associated with high risk of breast cancer.
Melissa C Southey, Zhi L Teo, James G Dowty, Fabrice A Odefrey, Daniel J Park, Marc Tischkowitz, Nelly Sabbaghian, Carmel Apicella, Graham B Byrnes, Ingrid Winship,[...]. Breast Cancer Res 2010
84
5

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Barbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, Rochelle Garcia, Jenny Gross, Wataru Sakai, Beth Y Karlan, Toshiyasu Taniguchi, Elizabeth M Swisher. J Clin Oncol 2011
347
5

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
David D Bowtell, Steffen Böhm, Ahmed A Ahmed, Paul-Joseph Aspuria, Robert C Bast, Valerie Beral, Jonathan S Berek, Michael J Birrer, Sarah Blagden, Michael A Bookman,[...]. Nat Rev Cancer 2015
440
5

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
308
5

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
284
5

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E Garber, Christina Herold, Leif Ellisen,[...]. Cancer 2015
246
5

Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
Kelly D Gonzalez, Katie A Noltner, Carolyn H Buzin, Dongqing Gu, Cindy Y Wen-Fong, Vu Q Nguyen, Jennifer H Han, Katrina Lowstuter, Jeffrey Longmate, Steve S Sommer,[...]. J Clin Oncol 2009
330
5


Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
Matthew B Yurgelun, Matthew H Kulke, Charles S Fuchs, Brian A Allen, Hajime Uno, Jason L Hornick, Chinedu I Ukaegbu, Lauren K Brais, Philip G McNamara, Robert J Mayer,[...]. J Clin Oncol 2017
156
5

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Diana Mandelker, Liying Zhang, Yelena Kemel, Zsofia K Stadler, Vijai Joseph, Ahmet Zehir, Nisha Pradhan, Angela Arnold, Michael F Walsh, Yirong Li,[...]. JAMA 2017
169
5

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Mark E Robson, Angela R Bradbury, Banu Arun, Susan M Domchek, James M Ford, Heather L Hampel, Stephen M Lipkin, Sapna Syngal, Dana S Wollins, Noralane M Lindor. J Clin Oncol 2015
283
5


Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Heather Hampel, Wendy L Frankel, Edward Martin, Mark Arnold, Karamjit Khanduja, Philip Kuebler, Hidewaki Nakagawa, Kaisa Sotamaa, Thomas W Prior, Judith Westman,[...]. N Engl J Med 2005
889
5

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Sushmita Gordhandas, Barbara M Norquist, Kathryn P Pennington, Rachel L Yung, Mary B Laya, Elizabeth M Swisher. Gynecol Oncol 2019
27
18

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Douglas F Easton, Fabienne Lesueur, Brennan Decker, Kyriaki Michailidou, Jun Li, Jamie Allen, Craig Luccarini, Karen A Pooley, Mitul Shah, Manjeet K Bolla,[...]. J Med Genet 2016
64
7

Pathogenic Germline Variants in 10,389 Adult Cancers.
Kuan-Lin Huang, R Jay Mashl, Yige Wu, Deborah I Ritter, Jiayin Wang, Clara Oh, Marta Paczkowska, Sheila Reynolds, Matthew A Wyczalkowski, Ninad Oak,[...]. Cell 2018
226
5

Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
Piera Rizzolo, Veronica Zelli, Valentina Silvestri, Virginia Valentini, Ines Zanna, Simonetta Bianchi, Giovanna Masala, Alessandro Mauro Spinelli, Maria Grazia Tibiletti, Antonio Russo,[...]. Int J Cancer 2019
19
26

The Tumor Suppressor PALB2: Inside Out.
Mandy Ducy, Laura Sesma-Sanz, Laure Guitton-Sert, Anahita Lashgari, Yuandi Gao, Nadine Brahiti, Amélie Rodrigue, Guillaume Margaillan, Marie-Christine Caron, Jacques Côté,[...]. Trends Biochem Sci 2019
45
11

Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
T K Foo, M Tischkowitz, S Simhadri, T Boshari, N Zayed, K A Burke, S H Berman, P Blecua, N Riaz, Y Huo,[...]. Oncogene 2017
45
11

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
John K Chan, Mark F Brady, Richard T Penson, Helen Huang, Michael J Birrer, Joan L Walker, Paul A DiSilvestro, Stephen C Rubin, Lainie P Martin, Susan A Davidson,[...]. N Engl J Med 2016
189
5

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015
344
5

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
David W Kindelberger, Yonghee Lee, Alexander Miron, Michelle S Hirsch, Colleen Feltmate, Fabiola Medeiros, Michael J Callahan, Elizabeth O Garner, Robert W Gordon, Chandler Birch,[...]. Am J Surg Pathol 2007
696
5

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
5

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
Takayuki Enomoto, Daisuke Aoki, Kana Hattori, Masahisa Jinushi, Junzo Kigawa, Nobuhiro Takeshima, Hitoshi Tsuda, Yoh Watanabe, Kosuke Yoshihara, Toru Sugiyama. Int J Gynecol Cancer 2019
27
18

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
H A Risch, J R McLaughlin, D E Cole, B Rosen, L Bradley, E Kwan, E Jack, D J Vesprini, G Kuperstein, J L Abrahamson,[...]. Am J Hum Genet 2001
707
5

Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Amy Finch, Patricia Shaw, Barry Rosen, Joan Murphy, Steven A Narod, Terence J Colgan. Gynecol Oncol 2006
256
5

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
859
5

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski,[...]. Cancers (Basel) 2018
17
29

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Sandra Bonache, Irene Esteban, Alejandro Moles-Fernández, Anna Tenés, Laura Duran-Lozano, Gemma Montalban, Vanessa Bach, Estela Carrasco, Neus Gadea, Adrià López-Fernández,[...]. J Cancer Res Clin Oncol 2018
24
20

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
120
5

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
250
5

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
337
4

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.
Angela Toss, Chiara Tomasello, Elisabetta Razzaboni, Giannina Contu, Giovanni Grandi, Angelo Cagnacci, Russell J Schilder, Laura Cortesi. Biomed Res Int 2015
71
5

Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Magdalena Ratajska, Ewelina Antoszewska, Anna Piskorz, Izabela Brozek, Åke Borg, Hanna Kusmierek, Wojciech Biernat, Janusz Limon. Breast Cancer Res Treat 2012
60
6

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
322
4

BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.
S B Cantor, D W Bell, S Ganesan, E M Kass, R Drapkin, S Grossman, D C Wahrer, D C Sgroi, W S Lane, D A Haber,[...]. Cell 2001
475
4

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
B A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, M G E M Ausems, J M Collée, H C van Doorn, E B Gomez Garcia, C M Kets, F E van Leeuwen, H E J Meijers-Heijboer,[...]. J Natl Cancer Inst 2015
109
4

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Catherine M Phelan, Karoline B Kuchenbaecker, Jonathan P Tyrer, Siddhartha P Kar, Kate Lawrenson, Stacey J Winham, Joe Dennis, Ailith Pirie, Marjorie J Riggan, Ganna Chornokur,[...]. Nat Genet 2017
121
4

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Lindsey E Minion, Jill S Dolinsky, Dana M Chase, Charles L Dunlop, Elizabeth C Chao, Bradley J Monk. Gynecol Oncol 2015
64
6

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
749
4

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang. Clin Cancer Res 2015
94
4

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.
Kate Lawrenson, Edwin S Iversen, Jonathan Tyrer, Rachel Palmieri Weber, Patrick Concannon, Dennis J Hazelett, Qiyuan Li, Jeffrey R Marks, Andrew Berchuck, Janet M Lee,[...]. Carcinogenesis 2015
19
21

A systematic review and meta-analysis of family history and risk of ovarian cancer.
J F Stratton, P Pharoah, S K Smith, D Easton, B A Ponder. Br J Obstet Gynaecol 1998
138
4

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018
68
5

Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Adam N Rosenthal, Lindsay S M Fraser, Susan Philpott, Ranjit Manchanda, Matthew Burnell, Philip Badman, Richard Hadwin, Ivana Rizzuto, Elizabeth Benjamin, Naveena Singh,[...]. J Clin Oncol 2017
67
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.